C4 Therapeutics Inc Ordinary Shares CCCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
-
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
-
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
-
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
-
C4 Therapeutics to Participate in Upcoming September Investor Conferences
-
C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation
-
C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
-
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
Trading Information
- Previous Close Price
- $5.90
- Day Range
- $5.69–6.07
- 52-Week Range
- $1.06–11.85
- Bid/Ask
- $5.73 / $5.75
- Market Cap
- $398.00 Mil
- Volume/Avg
- 279,546 / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 11.91
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 145
- Website
- https://www.c4therapeutics.com
Comparables
Valuation
|
Metric
|
CCCC
|
ARTV
|
JANX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.64 | — | 3.67 |
Price/Sales | 11.91 | 3.88 | 149.79 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CCCC
|
ARTV
|
JANX
|
|---|---|---|---|
Quick Ratio | 4.89 | 4.43 | 57.02 |
Current Ratio | 5.09 | 4.59 | 57.34 |
Interest Coverage | −715.67 | — | — |
Quick Ratio
CCCC
ARTV
JANX
Profitability
|
Metric
|
CCCC
|
ARTV
|
JANX
|
|---|---|---|---|
Return on Assets (Normalized) | −22.53% | −16.21% | −4.75% |
Return on Equity (Normalized) | −34.97% | — | −5.12% |
Return on Invested Capital (Normalized) | −30.08% | — | −9.37% |
Return on Assets
CCCC
ARTV
JANX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Hvzhpxkwz | Wzncy | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dvhtvzf | Jlsyvd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nvyvhttg | Lfhzdfs | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tfkxdby | Tjntl | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Vxnbyjpz | Xwf | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Wnltvtmc | Lmhdc | $28.1 Bil | |||
| Moderna Inc
MRNA
| Sjkqzszvh | Xldp | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Kcclxnjqb | Vbpzk | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Swpslmcrb | Bspfd | $13.4 Bil | |||
| Incyte Corp
INCY
| Lwlwhbjm | Qbznvh | $12.7 Bil |
United States